We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » FDA Rejects Ardelyx Chronic Kidney Disease Drug
The FDA has denied Ardelyx’s new drug application (NDA) for tenapanor as a treatment for chronic kidney disease in adults on dialysis, citing concerns over the treatment’s effectiveness.